Rejuvenation Technologies Inc.

Summer 2018Active

mRNA therapeutics to extend healthspan entering clinical trials

Save

Rejuvenation Technologies Inc.

Summer 2018Active

mRNA therapeutics to extend healthspan entering clinical trials

Save

Company details

Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months.

Location

San Francisco, CA, USA

Founded

Unknown

Upgrade to Pro, then request the Rejuvenation Technologies Inc. teardown.

This company does not have a completed analysis yet. Choose a Pro plan first, then use one of your 5 monthly research requests to have our agent investigate Rejuvenation Technologies Inc.. The full teardown, rebuild plan, and technical specs unlock when it lands.

Use Pro to request the first Rejuvenation Technologies Inc. teardown and keep the finished report in your account.
Read every completed teardown and rebuild plan already in the database.
Unlock implementation-ready technical specs and 5 fresh research requests each month.

Choose your Pro plan

$20/ month

Find one worth rebuilding, get the teardown, open the implementation-ready specs, and use fresh report requests when you want deeper research.

See Pro plans

Full teardown library

Specs for every company

5 fresh requests / month

CLI for agent imports